drugset / Trial / NCT04110873
A Phase II, Placebo-controlled Trial Evaluating the Efficacy of Antroquinonol in Patients With Atopic Dermatitis
Phase 2
Terminated
14 enrolled
Chung Shan Medical University
Golden Biotechnology Corporation · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Primary Objective: To evaluate the activity of Antroquinonol in patients with atopic dermatitis. Secondary Objective: To assess the mechanism and cytokines change of Antroquinonol in patients with atopic dermatitis. Exploratory Objective: To explore potential relationships between Antroquinonol exposure and safety and efficacy endpoints.
Timeline
- Start
- 2018-07-27
- Primary completion
- 2019-06-25
- Completion
- 2019-06-25
Outcome
Outcome not reported
Stopped (Enrollment): “It was hard to find suitable subject due to strict enrollment criteria.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Antroquinonol | Small molecule | 50 mg | — |
| Subject | Antroquinonol | Small molecule | 100 mg | — |